Investors
Roche’s 3rd Quarter Sales 2025 Presentation
Roche has published its Third Quarter Sales for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 23rd October 2025.
Please click here to watch the replay of the webinar.
Presentation download
Presentation download with appendix
:quality(90)/)
Roche’s Virtual Ophthalmology Investor Event
Roche has hosted a virtual event on Tuesday, 21 October 2025
Please click here to watch the replay
Presentation download
:quality(90)/)
24 million
patients were treated with Roche medicines in 2024
30 billion
Roche Diagnostics test were delivered to customers worldwide in 2024
+1%
Core investments in research and development in 2024: CHF 13.2 billion
Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
:quality(90)/)
Investor updates
Upcoming Investor events
View all eventsLatest reports
:quality(90)/)
:quality(90)/)
Investor relations team contacts
Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.